JPS562917A - Stabilization of sulfonated immunoglobulin - Google Patents

Stabilization of sulfonated immunoglobulin

Info

Publication number
JPS562917A
JPS562917A JP7673479A JP7673479A JPS562917A JP S562917 A JPS562917 A JP S562917A JP 7673479 A JP7673479 A JP 7673479A JP 7673479 A JP7673479 A JP 7673479A JP S562917 A JPS562917 A JP S562917A
Authority
JP
Japan
Prior art keywords
sulfonated
stabilization
immoglobulin
stabilize
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP7673479A
Other languages
Japanese (ja)
Other versions
JPS6220965B2 (en
Inventor
Tsunemasa Yoshida
Shoji Ono
Yuji Fukumoto
Yoshio Ishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Teijin Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to JP7673479A priority Critical patent/JPS562917A/en
Publication of JPS562917A publication Critical patent/JPS562917A/en
Publication of JPS6220965B2 publication Critical patent/JPS6220965B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PURPOSE: To stabilize the title sulfonated immoglobulin (S), by adding serum albumin etc. to S as a stabilizer.
CONSTITUTION: 0.01W1.0pt.wt of serum albumin, and if necessary 0.2W1.0pt.wt. of glycine and/or 0.04wt% of mannitol, are added to stabilize 1pt.wt. of sulfonated immoglobulin. The method prevents the problems of increase in aggregates in dialysis, transportation and freeze-drying steps by the mechanical or thermal denaturation or opacifying of a solution leading to the increase in anticomplementary value of the final product.
COPYRIGHT: (C)1981,JPO&Japio
JP7673479A 1979-06-20 1979-06-20 Stabilization of sulfonated immunoglobulin Granted JPS562917A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7673479A JPS562917A (en) 1979-06-20 1979-06-20 Stabilization of sulfonated immunoglobulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7673479A JPS562917A (en) 1979-06-20 1979-06-20 Stabilization of sulfonated immunoglobulin

Publications (2)

Publication Number Publication Date
JPS562917A true JPS562917A (en) 1981-01-13
JPS6220965B2 JPS6220965B2 (en) 1987-05-11

Family

ID=13613808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7673479A Granted JPS562917A (en) 1979-06-20 1979-06-20 Stabilization of sulfonated immunoglobulin

Country Status (1)

Country Link
JP (1) JPS562917A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58192830A (en) * 1982-05-04 1983-11-10 Teijin Ltd Remedy for thrombocytopenia
US6165467A (en) * 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58192830A (en) * 1982-05-04 1983-11-10 Teijin Ltd Remedy for thrombocytopenia
US6165467A (en) * 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation

Also Published As

Publication number Publication date
JPS6220965B2 (en) 1987-05-11

Similar Documents

Publication Publication Date Title
RU93046317A (en) CHINDROITINASE, METHOD FOR ITS PREPARATION AND CONTENTS OF ITS PHARMACEUTICAL COMPOSITIONS
EP0270025A3 (en) Process for the preparation of an intravenously administrable immunoglobulin stable in the liquid phase
ES537578A0 (en) PROCEDURE FOR THE STABILIZATION OF PHARMACEUTICAL PREPARATIONS IN THE FORM OF SUSPENSIONS CONTAINING SUCRALPHATE
DE3867046D1 (en) METHOD FOR PURIFYING SERUM ALBUMINE.
KR900005987A (en) Some medicinal preparations and preparation method thereof
GR3003631T3 (en)
CA2037884A1 (en) Stabilized gonadotropin containing preparations
SE7904118L (en) WAY TO PREPARE A UROKINA COMPOSITION
NO922953D0 (en) RECOMBINANT MANUFACTURED BLOOD FACTORS AND PROCEDURE FOR EXPRESSION OF BLOOD FACTORS, AND VACCINIA VIRUS RECOMBINANTS
EP0410207A3 (en) Stabilization of highly purified proteins
IT1241153B (en) METHOD FOR PREPARING STABLE BITUMEN-POLYMER MIXTURES
DE3261832D1 (en) Method for the stabilisation of peroxidase in a liquid medium, and the stabilised medium so obtained
IE791033L (en) Stabilised milk compositions
AU679581B2 (en) Method of stabilizing protein C or activated protein C and stabilized composition
EP0258111A3 (en) Novel neuronotrophic factor
GB941019A (en) Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
WO1990003172A3 (en) Bile acids for treatment of viral infections
EP0327769A3 (en) Novel neuronotrophic factor
Wolkoff et al. Purification of ligandin by affinity chromatography on sulfobromophthalein-agarose gel
Okuyama Mechanism of increase of the cerebrospinal fluid (CSF) protein content in Guillain-Barre syndrome. Study using RISA in evaluation of diffusion within CSF cavity and transport of CSF to circulating plasms
DK150481C (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 3 ', 4'-DIHYDRO-SPIRO- (IMIDAZOLIDIN-4,1' - (2'H) -NAPHTHALEN) -5-ON OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS THEREOF
EP0063353A3 (en) Highly purified messenger ribonucleic acid (m-rna), process for preparing it and its use
Kosovinc Constitution of the Cd--Sn--Sb System
Lagrue et al. Lymphokine'skin reactive factor'(SRF) and the nephrotic syndrome
JPS55133318A (en) Immunosuppressive agent and its preparation